(2023)
Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer.
Oncology Research.
31,
6
(2023)
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients.
EUROPEAN JOURNAL OF CANCER.
189,
(2022)
A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer.
Clinical Oncology.
34,
8
(2022)
The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY.
14,
(2022)
Safety and Efficacy of Liver-Directed Radiotherapy in Combination With Lenvatinib for Hepatocelluar Carcinoma With Macroscopic Tumor Thrombosis.
FRONTIERS IN ONCOLOGY.
12,
(2022)
Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer.
ANNALS OF SURGICAL ONCOLOGY.
-,
-
(2022)
Safety and anti-tumor effects of vismodegib in patients with refractory advanced gastric cancer: A single-arm phase-II trial.
JOURNAL OF CANCER.
13,
4
(2021)
The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers.
FRONTIERS IN ONCOLOGY.
11,
(2021)
Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma.
LIVER INTERNATIONAL.
42,
3
(2021)
Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab.
CANCER IMMUNOLOGY IMMUNOTHERAPY.
70,
6
(2021)
Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein >= 400 ng/mL: A Matching-Adjusted Indirect Comparison.
ADVANCES IN THERAPY.
38,
5
(2021)
Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240.
CANCER.
127,
6
(2021)
A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial.
ANNALS OF ONCOLOGY.
32,
3
(2021)
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial.
EUROPEAN UROLOGY.
79,
3
(2021)
ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy.
IN VIVO.
35,
1
(2021)
Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
JOURNAL OF HEPATOLOGY.
74,
2
(2021)
Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer.
JOURNAL OF CANCER.
12,
2
(2020)
Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY.
12,
-
(2020)
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial.
JAMA ONCOLOGY.
6,
11
(2020)
Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors.
EXPERT OPINION ON INVESTIGATIONAL DRUGS.
29,
9
특허/프로그램
위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
{MARKER FOR PREDICTING STOMACH CANCER PROGNOSIS AND METHOD FOR PREDICTING STOMACH CANCER PROGNOSIS}.
11849123.2.
20180808.
폴란드
위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
{MARKER FOR PREDICTING STOMACH CANCER PROGNOSIS AND METHOD FOR PREDICTING STOMACH CANCER PROGNOSIS}.
11849123.2.
20180808.
독일
위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
{MARKER FOR PREDICTING STOMACH CANCER PROGNOSIS AND METHOD FOR PREDICTING STOMACH CANCER PROGNOSIS}.
11849123.2.
20180808.
스페인
학술회의논문
(2009)
MET amplification by qPCR predicts poor outcome in gastric cancer: a novel
prognostic marker and a potential therapeutic target.
EUROPEAN JOURNAL.
독일
(2009)
Prognostic model to predict outcomes in pancreatic adenocarcimoma patients
who received surgical resection with curative intent.
EUROPEAN JOURNAL.
독일
(2009)
Impact of MET amplification on gastric cancer: A novel prognostic marker and a potential therapeutic
arget.
100TH AACR ANNUAL MEETING.
미국
(2009)
Definitive chemoradiation therapy with capecitabine in locally
advanced pancreatic cancer.
2009 Gastroinotesinal Cancer Symposium.
미국
(2008)
A Phase I/II Trial of docetaxel and oxaliplatin in patienes with advanced gastric cancer.
ASCO.
미국
(2008)
A Phase II study of oxaliplatin in combination with doxorubicine as first-line chemotherapy in patients with inoperable hepatocellular carcioma..
ASCO.
미국
(2008)
Gemcitabine and oxaliplatin combination as the first-line treament in advanced pancreatic cancer: A multicenter phase ll.
ASCO.
미국
